Figure 6: Respective dominance of MyD88/canonical and TRIF/noncanonical NF-κB signalling pathways as induced by immunostimulant and immunosuppressive CpG.
From: High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9–TRIF pathway
(a) Low-dose CpG activates phosphorylation of IKKα and IKKβ whereas higher-dose CpG activates phosphorylation of IKKα. pDCs were treated with 1 or 10 μg ml−1 CpG for different times and immunoblots of cell lysates were probed with anti-pIKKα/β followed by anti-IKKα or anti-IKKβ. One experiment representative of three. ELISA measurements were used to determine the relative amounts (A450) of p65 and p52 in pDCs treated with low-dose CpG (b) or high-dose CpG (c) as above for different times. Nuclear extracts were obtained from cells of WT or genetically deficient mice. Data are means±s.d. of three experiments. *P<0.05–0.01 (treatment versus respective time 0 control; Student’s t-test).
